MONTREAL, April 29 /PRNewswire-FirstCall/ - CryoCath , the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that it recently achieved the target of consenting 270 patients for the Company’s Arctic Front(R) STOP AF IDE pivotal trial in the U.S.
“We are very pleased to have achieved this important milestone,” said Jean Pierre Desmarais, Chief Scientific Officer of CryoCath. “Both the body of strong clinical evidence as well as commercial acceptance continue to grow rapidly in Europe and other parts of the world. We look forward to obtaining 12 month follow up data, gaining PMA approval, and be able to make our innovative technology available to millions of Paroxysmal Atrial Fibrillation patients in the United States.”
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.
CONTACT: For further information: visit our website at www.cryocath.com,
or contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext.
241, Fax: (416) 815-0080, E-mail: mmoore@equicomgroup.com